

I/We claim:

1. An inhalable dry powder composition consisting of:
 - (a) glycopyrronium bromide, formoterol fumarate dihydrate, and fluticasone propionate, wherein the ratio of glycopyrronium bromide, formoterol fumarate, and fluticasone propionate ranges from 0.8-2.5:1:15-25 and
 - (b) excipient consisting of 0.1 to 10 % w/w of fine lactose particles having particle size D90 in the range of 4-50 μ m; and 90 to 99.9 % w/w of coarse lactose particles having particle size D90 in the range of 150-200 μ m, wherein the weight ratio of fine lactose particles to coarse lactose particles ranges from 1:15 to 1:40.
2. The inhalable dry powder composition as claimed in claim 1, wherein (i) fine lactose particles having average particle size D50 in the range of 2-20 μ m; and (ii) coarse lactose particles having average particle size D50 in the range of 80-130 μ m.
3. A process for preparing an inhalable dry powder composition as claimed in claim 1, the process comprising:
 - (i) mixing glycopyrronium bromide, formoterol fumarate dihydrate and fluticasone propionate with fine lactose particles;
 - (ii) blending the mixture obtained in step (i) with coarse lactose particles and
 - (iii) filling the blend of step (ii) in a capsule or a blister.
4. The process as claimed in claim 3, wherein the process does not include any step of co-micronization.
5. The process as claimed in claim 3, wherein glycopyrronium bromide, formoterol fumarate dihydrate and fluticasone propionate are in micronized form having D50 value of each drug in the range of 1 μ m to 4 μ m and/or D90 value of each drug in the range of 2 μ m to 6 μ m.
6. The process as claimed in claim 3, wherein the composition has D50 values in the range of 50 μ m to 120 μ m or in the range of 70 μ m to 100 μ m.
7. The process as claimed in claim 3, wherein the composition has D90 values in the range of 120 μ m to 200 μ m or in the range of 150 μ m to 180 μ m.

8. The process as claimed in claim 3, wherein the composition has fine particle mass having particle size between 1 μm to 50 μm is in the range of 5% to 30% and/or coarse particle mass having particle size between 80 μm to 250 μm is in the range of 20% to 90%w/w.

9. The process as claimed in claim 3, wherein the composition has a bulk density in the range of 0.3 g/ml to 1 g/ml and/or a tapped density in the range of 0.5 g/ml to 1.25 g/ml.

10. The inhalable dry powder composition as claimed in claim 1 wherein, (i) the fine lactose particles have a D50 of 2 μm to 20 μm , and (ii) the coarse lactose particles have a D50 of from about 80 μm to 130 μm .

11. The inhalable dry powder composition as claimed in claim 1, wherein (i) the composition, when tested for aerodynamic particle size distribution, results in a fine particle mass for (a) glycopyrronium bromide of from 2 μg to 5 μg , (b) formoterol fumarate of from 2 μg to 5 μg , and (c) fluticasone propionate of from 45 μg to 70 μg .

12. The inhalable dry powder composition as claimed in claim 10, wherein the fine lactose particles have a D50 of from 2 μm to about 10 μm .

13. The inhalable dry powder composition as claimed in claim 10, wherein the coarse lactose particles have a D50 of from 95 μm to 125 μm .

Dated this **4th** day **of August 2020**



Garima Sahney

IN/PA 1826

Agent for the Applicant
of Saikrishna & Associates